FDA Requires New Kidney Injury Warning for All GLP-1 Drugs
The FDA is requiring warning label changes to all glucagon-like peptide 1 (GLP-1) receptor agonist medications – a class of drugs used for the treatment of diabetes and obesity – regarding the risk of serious kidney injury that can result from dehydration. This warning comes after the FDA received multiple reports from individuals who used these medications. Side effects of GLP-1 receptor agonists can include gastrointestinal issues such as vomiting, diarrhea, and nausea, which can result in volume loss. In more extreme cases, this can result in dehydration. Healthcare providers are advised to look for signs of renal function decline in patients taking GLP-1 receptor agonists. Patients are recommended to stop taking GLP-1 receptor agonists at the first sign of dehydration or kidney issues – such as dark urine, infrequent urination and dizziness – and to seek medical care.
